...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Urology >RRM1 predicts clinical outcome of high-and?intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
【24h】

RRM1 predicts clinical outcome of high-and?intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy

机译：RRM1预测接受吉西他滨单一治疗的高危和中危非肌肉浸润性膀胱癌患者的临床结局

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The expression level of ribonucleotide reductase subunit M1 (RRM1) is closely related to the effect of gemcitabine-based therapy in advanced bladder cancer. However, the value of RRM1 expression in predicting progression-free survival in non-muscle-invasive bladder cancer (NMIBC) patients treated with intravesical gemcitabine chemotherapy has not been elucidated. This study randomly assigned 162 patients to either the RRM1-known group or the unknown group. We collected cancer tissues from 81 patients to evaluate the mRNA expression of RRM1 by using liquid chip technology. All patients were diagnosed and then treated with intravesical gemcitabine monotherapy immediately after transurethral resection of the bladder tumour (TURBT). RRM1 expression was high in 21% (17/81) of patients. The RRM1 mRNA level was not correlated with sex, age, weight, performance status, or CUA/EAU risk (p??0.05). Progression-free survival (PFS) was significantly longer for patients with low RRM1 expression than for patients with high and unknown RRM1 expression (p?=?0.009). Additionally, the 1- and 2-year relapse rates also differed according to RRM1 expression level. The 1-year relapse rates for RRM1-low, RRM1-high and RRM1-unknown patients were 0, 17.7 and 6.2% (p?=?0.009), while the 2-year relapse rates for these groups were 3.1, 29.4, and 11.1% (p?=?0.005), respectively. This preliminary study showed that low RRM1 expression was associated with longer progression-free survival and lower 1-year/2-year relapse rates in NMIBC patients treated with intravesical gemcitabine monotherapy, despite the need for further verification with large sample sizes and considering more mixed factors and biases.
机译：核糖核苷酸还原酶亚基M1（RRM1​​）的表达水平与吉西他滨治疗晚期膀胱癌的效果密切相关。但是，尚未阐明RRM1表达在预测接受吉西他滨膀胱内化疗的非肌肉浸润性膀胱癌（NMIBC）患者的无进展生存中的价值。该研究将162名患者随机分配到RRM1已知组或未知组。我们使用液体芯片技术收集了81位患者的癌组织，以评估RRM1的mRNA表达。经尿道膀胱肿瘤切除术（TURBT）后，所有患者均被确诊，然后立即行膀胱内吉西他滨单药治疗。 RRM1表达在21％（17/81）的患者中较高。 RRM1 mRNA水平与性别，年龄，体重，工作状态或CUA / EAU风险无关（p≥0.05）。 RRM1低表达患者的无进展生存期（PFS）明显高于RRM1高表达和未知患者（p？=？0.009）。此外，根据RRM1表达水平，一年和两年复发率也有所不同。 RRM1低，RRM1高和RRM1未知患者的1年复发率分别为0、17.7和6.2％（p？=？0.009），而这些组的2年复发率分别为3.1、29.4和分别为11.1％（p≤0.005）。这项初步研究表明，尽管需要通过大样本量进行进一步验证并考虑更多混合药物，在接受膀胱吉西他滨单药治疗的NMIBC患者中，RRM1低表达与更长的无进展生存期和更低的1年/ 2年复发率相关。因素和偏见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号